Navigation Links
Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
Date:5/5/2010

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. Furthermore, the results associated CD24 expression with the new (seventh) edition of the TNM staging. In summary, the study concluded that high expression of CD24 was a negative independent prognostic factor for progression free and cancer-specific survival in NSCLC.

The metastasis-associated protein CD24 found within a tumor has been identified as a new prognostic factor and stem cell marker; however, the importance of the CD24 in NSCLCs has not been made clear through previously existing research. To clarify the understanding, the present study conducted a retrospective study of prognostic factor analysis by evaluating CD24 expression in 267 consecutive cases of NSCLC. Using a tissue microarray technique the team analyzed the immunohistochemistry that correlated with clinicopathologic parameters.

The specific study findings revealed that CD24-high expression was demonstrated in 33 percent of the NSCLC cases, specifically 87 of 267. Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology (23 percent). Patients with CD24-high tumors also tended to have a higher risk of disease progression and cancer-related death. Furthermore, CD24-high expression aligned with new pathologic stages rather than old p-stages.

Prior to the revision of the TNM staging, the most important conventional prognostic factor for patient survival was tumor stage at the time of diagnosis, including tumor size, pleura invasion, involvement of regional lymph nodes and metastatic spread to distant organs. However, the revised guidelines found age, gender and performance status (PS), in addition to stage, all to be prognostic factors for survival. Within the current study, expression correlated with PS and new p-stage; furthermore, age correlated with progression free survival and cancer-specific survival, regardless of tumor histology.

"Biomarkers that are over-expressed during cancer progression are of special interest because they may not only be used to predict patient outcome but also serve as potential targets in cancer therapy like epidermal growth factor receptor (EGFR) gene," lead investigator Dr. Hyun Ju Lee relays the implications of the research findings.


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after ... Public Television. “Informed” brings the public important topics from all aspects of life, and ... feet and issues surrounding feet and ankles. , Podiatry is essential to people’s overall ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Technique, technique, technique ... injury when either lifting weights for strength training and exercise or simply lifting heavy ... . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting anything ...
(Date:5/23/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor in ... address potential cybersecurity threats before they happen. The annual list of top ...
(Date:5/23/2017)... ... 2017 , ... Cambridge, MA, May 23, 2017—Total costs per ... a Workers Compensation Research Institute (WCRI) study, a contrast from the increases of ... Benchmarks, 17th Edition looks at indemnity and medical payments for workers’ compensation ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council ... pleased to announce the organization’s Certified Strength Coach credential has earned accreditation from ... (CSC) program validates the competency of qualified candidates for jobs in the Strength ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)... May 3, 2017  Kalorama Information notes that ... percent next year and this is projected to ... stem cell (HSCT) or bone marrow transplants require ... are well-suited for this task. This according to ... Kalorama Information. The various PCR-based methodologies, Sanger sequencing ...
(Date:5/2/2017)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce a ... AB that allows for the marketing and distribution ... analyses through the MarketResearch.com website. The new ... to complete product descriptions and tables of contents from ...
Breaking Medicine Technology: